DexCom, Inc. Earnings Recaps
Q3 2025
Nov 1, 2025
DexCom reported strong third-quarter 2025 results with 20% organic revenue growth, driven by expanding customer access and innovative product offerings in the continuous glucose monitoring (CGM) space.
Key takeaways
- Achieved 20% organic revenue growth year-over-year, reflecting robust market demand and competitive positioning.
- Expanded CGM access to nearly 6 million U.S. type 2 diabetes patients, targeting full coverage for over 25 million individuals.
- Introduced DexCom Smart Basal, an innovative titration module designed to enhance basal insulin management and improve patient adherence.
- Stelo product surpassed $100 million in revenue within its first year, indicating strong market traction and consumer interest in CGM for metabolic health.
- Continued advancement of G7 15-day system rollout, bolstered by successful reimbursement strategies.
Q2 2025
Aug 1, 2025
DexCom achieved a robust 15% organic revenue growth in Q2 2025, driven by strong demand in the U.S. and significant progress in expanding insurance coverage for type 2 diabetes patients.
Key takeaways
- Launched type 2 non-insulin reimbursement, establishing coverage for nearly 6 million patients through the three largest PBMs in the U.S.
- Strong market share growth driven by heightened sales force effectiveness and increased access to healthcare providers.
- Over 400,000 downloads of the Stelo app reflect growing consumer interest in glucose monitoring and health wearables.
- Anticipating a successful second-half launch of the 15-day G7 System, with FDA clearance and reimbursement discussions on track.
- Introduced innovative AI features across products to enhance user experience and simplify diabetes management.